Presentation at the Society for Technology in Anesthesia Annual Meeting
Quantifies Decreases in Rescue Calls and ICU Transfers with Improved ICU
Utilization
IRVINE, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI),
the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion
pulse oximetry, today announced that a team of clinicians at
Dartmouth-Hitchcock Medical Center (DHMC) presented new outcome data from
their year-long implementation study showing Masimo Rainbow SET Pulse
CO-Oximetry and Patient SafetyNet remote monitoring and clinician notification
system helps improve patient outcomes and reduce the cost of care by
decreasing rescue calls and ICU transfers, resulting in improved ICU
utilization. Study findings were presented at the Society for Technology in
Anesthesia (STA) Annual Meeting in San Antonio, Texas on January 15, 2009.
Clinical data tracked by Dr. George T. Blike, Medical Director of Patient
Safety, and his team at DHMC during the 12-month study period showed that,
after the implementation of Masimo Rainbow SET and Patient SafetyNet, there
was a 70% reduction in rescue calls and a 48% reduction in ICU transfers. In
addition, the team found that the reduction in ICU transfers helped to free up
an estimated 163 ICU-days annually for its 36-bed post-surgical unit, thereby
increasing ICU access for more critically ill patients. The findings and data
also indicate that there is a measurable cost advantage associated with Masimo
Patient SafetyNet's ability to assist clinicians in the identification of the
onset of patient distress earlier -- preventing codes, rescues, and ICU
transfers -- contributing to significant decreases in patient care costs on
the general care floor.
Financial data presented by the team showed that the cost of care for
patients undergoing bilateral or multiple major joint prosthesis operations of
the lower extremity who did not deteriorate to the point of rescue was 60%
less ($19,987) than the cost of care for patients who did ($49,602).
Additionally, the length of stay for non-rescued patients was 68% shorter than
that of rescued patients (3.9 days versus 12.3 days). For major joint
replacement operations of the lower extremity, the length of stay for patients
who did not require a rescue call was 38% shorter (3.6 days versus 5.8 days),
which resulted in a 31% decrease in their cost of care ($13,648 versus
$19,765).
George T. Blike, M.D., Medical Director of Patient Safety at DHMC, stated;
"The data tracked in this 12-month study demonstrates that routine patient
monitoring on the general care floor using Masimo Rainbow SET and the Patient
SafetyNet system, with its ability to measure oxygen saturation continuously
and directly page a nurse when problems are identified, was associated with
statistically significant reductions in the need for urgent and emergent
interventions. Initial analysis shows we reduced the need for ICU transfers
and, we believe, the cost of care through early detection and intervention of
physiologic abnormalities. These results are such that we have expanded
implementation of the system to two additional post-surgical units."
The Masimo Patient SafetyNet system combines the "gold standard"
Measure-Through Motion and Low Perfusion performance of Masimo Rainbow SET
Pulse CO-Oximetry technology with wireless clinician alerts via pager to help
provide a new level of safety to patients on general care floors, where
nurse-to-patient ratios preclude the level of direct surveillance required and
recommended to preempt adverse events. When physiologic parameters
deteriorate, Masimo Patient SafetyNet system provides accurate, actionable
alarm notification directly to a qualified clinician--enabling immediate and
early intervention.
The growing frequency of unrecognized adverse incidents and avoidable
patient safety issues resulting in death or serious physical injury is a
preventable and costly human tragedy that the Journal of the American Medical
Association has reported may account for 2.4 million extra hospital days, over
32,500 deaths, and $9.3 billion in excess charges in the United States
annually.(1) These startling statistics have prompted the convergence of
leading healthcare accreditation and industry groups toward a common patient
safety standard of continuous, noninvasive physiologic monitoring linked to an
appropriate clinician alert and notification system for perioperative
patients.
The Joint Commission's National Patient Safety Goals call for the
"improved recognition and response to changes in a patient's condition" and
recommend "a suitable method that enables health care staff members to
directly request additional assistance from a specially trained individual(s)
when the patient's condition appears to be worsening."(2) The Anesthesia
Patient Safety Foundation (APSF) recommendations advise healthcare
professionals to "give consideration to the potential safety value of
continuous postoperative monitoring of oxygenation and ventilation in at-risk
patients without delay," urging that "it is critical that any monitoring
system be linked to a reliable process to summon a competent healthcare
professional to the patient's bedside in a timely manner."(3) The American
Society of Anesthesiologists (ASA) Clinical Practice Guidelines have
established that "continuous pulse oximetry monitoring in a step-down unit
reduces the likelihood of perioperative complications among patients who are
believed to be at increased perioperative risk from OSA."(4)
Masimo Founder and CEO, Joe E. Kiani, stated; "By revolutionizing pulse
oximetry with the invention of Signal Extraction Technology (SET), we created
a new era where pulse oximeters could measure through motion and low
perfusion, resulting in the virtual elimination of false alarms with an
increased ability to detect true events. The clinical community and Masimo
collectively hoped that our technology could help caring clinicians improve
the quality of care for their patients. In the last ten years, we have
witnessed our technology being used to help save the eyesight of neonates,
detect congenital heart defects in newborns and save countless lives. The
evidence gathered by Dr. Blike and his team at Dartmouth-Hitchcock Medical
Center continues to illustrate the substantial impact of Masimo technology on
patient safety benchmarks. These caring clinical professionals have done
their hospital and the medical community a great service by implementing a
solid protocol with Masimo Rainbow SET and Patient SafetyNet to more
effectively and efficiently care for their patients after surgery on the
general care floor. Their results provide a compelling case and opportunity
for hospitals to improve healthcare outcomes while decreasing costs."
A study published in the Journal of Critical Care Medicine estimates that
there are approximately 820,000 unmonitored beds in non-critical care settings
in the U.S.
(1) The Journal of the American Medical Association (JAMA). Excess Length
of Stay, Charges, Mortality Attributable to Medical Injuries During
Hospitalization, 2003.
(2) The Joint Commission: "Facts about the 2008 National Patient Safety
Goals"; June 1, 2007.
http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/08_nps
gs.htm
(3) Anesthesia Patient Safety Foundation (ASPF) Initiatives: "Safety
During Patient-Controlled Analgesia"; October 13, 2006.
www.apsf.org/initiatives/pca.mspx
(4) American Society of Anesthesiologists (ASA): "Practice Guidelines for
the Perioperative Management of Patients with Obstructive Sleep Apnea";
Anesthesiology 2006;104:1081-93.
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care--helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through Motion and Low Perfusion pulse
oximetry, known as Masimo SET, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks related to our
assumption that the positive results and clinical outcomes presented by
Dartmouth-Hitchcock Medical Center will be repeated at other hospitals, risks
related to our assumption that Masimo Patient SafetyNet will deliver a
sufficient level of clinical improvement over alternative remote monitoring
systems to allow for rapid adoption of the technology on general care floors,
as well as other factors discussed in the "Risk Factors" section of our
Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2008,
filed with the Securities and Exchange Commission ("SEC") on October 29, 2008,
which may be obtained for free at the SEC's website at www.sec.gov. Although
we believe that the expectations reflected in our forward-looking statements
are reasonable, we do not know whether our expectations will prove correct.
All forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any obligation to
update, amend or clarify these forward-looking statements or the "Risk
Factors" contained in our Quarterly Report on Form 10-Q for the fiscal quarter
ended September 27, 2008, whether as a result of new information, future
events or otherwise, except as may be required under the applicable securities
laws.
Contact:
Dana Banks
Masimo Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8,
Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered
trademarks of Masimo Corporation. CPT is a registered trademark of the
American Medical Association.
SOURCE Masimo
Web Site:
http://www.apsf.org/initiatives/pca.mspx
http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/08_npsgs.htm
http://www.masimo.com